SOME PATIENTS with advanced cancer tolerate skin homografts longer than normal.1-2 This is regarded as evidence of an impaired defense mechanism. We thought that perhaps a significant correlation could be found between the skin homograft rejection time and the clinical course of patients with cancer. Accordingly, we routinely applied skin grafts to all patients with primary cervical cancer admitted to the gynecology service. A full-thickness ellipse of skin, 0.6 × 1.0 cm, from another patient was applied to the forearm and held in place with a pressure dressing. The first sign of blanching or cyanosis was regarded as the end of survival. Grafts that survived 15 days or more were classified as prolonged. The frequency of prolonged survival in various types of patients is indicated in Tables 1 and 2. There were 107 patients who received no cancer treatment before the graft was applied or while it was in
Graham JB, Petersons N. Effect of Cancer Treatment on Skin Homograft Survival. JAMA. 1964;189(9):697–698. doi:10.1001/jama.1964.03070090047018
Customize your JAMA Network experience by selecting one or more topics from the list below.